449 related articles for article (PubMed ID: 26906522)
1. Inhibitor design against JNK1 through e-pharmacophore modeling docking and molecular dynamics simulations.
Katari SK; Natarajan P; Swargam S; Kanipakam H; Pasala C; Umamaheswari A
J Recept Signal Transduct Res; 2016 Dec; 36(6):558-571. PubMed ID: 26906522
[TBL] [Abstract][Full Text] [Related]
2. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
Natarajan P; Priyadarshini V; Pradhan D; Manne M; Swargam S; Kanipakam H; Bhuma V; Amineni U
J Recept Signal Transduct Res; 2016 Oct; 36(5):445-58. PubMed ID: 27305963
[TBL] [Abstract][Full Text] [Related]
3. Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies.
Ekhteiari Salmas R; Unlu A; Bektaş M; Yurtsever M; Mestanoglu M; Durdagi S
J Biomol Struct Dyn; 2017 Jul; 35(9):1899-1915. PubMed ID: 27315035
[TBL] [Abstract][Full Text] [Related]
4. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
6. Identification and neuroprotective evaluation of a potential c-Jun N-terminal kinase 3 inhibitor through structure-based virtual screening and in-vitro assay.
Rajan RK; Ramanathan M
J Comput Aided Mol Des; 2020 Jun; 34(6):671-682. PubMed ID: 32040807
[TBL] [Abstract][Full Text] [Related]
7. An integrated molecular modeling approach for in silico design of new tetracyclic derivatives as ALK inhibitors.
Peddi SR; Sivan SK; Manga V
J Recept Signal Transduct Res; 2016 Oct; 36(5):488-504. PubMed ID: 26758803
[TBL] [Abstract][Full Text] [Related]
8. Unravelling novel congeners from acetyllysine mimicking ligand targeting a lysine acetyltransferase PCAF bromodomain.
Suryanarayanan V; Singh SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4303-4319. PubMed ID: 29228881
[TBL] [Abstract][Full Text] [Related]
9. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Chaudhari HK; Pahelkar A
Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
[TBL] [Abstract][Full Text] [Related]
10. Molecular Docking, Molecular Dynamics Simulations, Computational Screening to Design Quorum Sensing Inhibitors Targeting LuxP of Vibrio harveyi and Its Biological Evaluation.
Rajamanikandan S; Jeyakanthan J; Srinivasan P
Appl Biochem Biotechnol; 2017 Jan; 181(1):192-218. PubMed ID: 27535409
[TBL] [Abstract][Full Text] [Related]
11. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.
Mirza SB; Lee RCH; Chu JJH; Salmas RE; Mavromoustakos T; Durdagi S
J Mol Graph Model; 2018 Jan; 79():88-102. PubMed ID: 29156382
[TBL] [Abstract][Full Text] [Related]
12. In silico trials to design potent inhibitors against matrilysin (MMP-7).
Katari SK; Pasala C; Nalamolu RM; Bitla AR; Umamaheswari A
J Biomol Struct Dyn; 2022; 40(22):11851-11862. PubMed ID: 34405760
[TBL] [Abstract][Full Text] [Related]
13. Understanding the specificity of a docking interaction between JNK1 and the scaffolding protein JIP1.
Yan C; Kaoud T; Lee S; Dalby KN; Ren P
J Phys Chem B; 2011 Feb; 115(6):1491-502. PubMed ID: 21261310
[TBL] [Abstract][Full Text] [Related]
14. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis for the Selective Inhibition of c-Jun N-Terminal Kinase 1 Determined by Rigid DARPin-DARPin Fusions.
Wu Y; Honegger A; Batyuk A; Mittl PRE; Plückthun A
J Mol Biol; 2018 Jul; 430(14):2128-2138. PubMed ID: 29126898
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
17. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics in drug design.
Zhao H; Caflisch A
Eur J Med Chem; 2015 Feb; 91():4-14. PubMed ID: 25108504
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel Plasmodium falciparum PI4KB inhibitors as potential anti-malarial drugs: Homology modeling, molecular docking and molecular dynamics simulations.
Ibrahim MAA; Abdelrahman AHM; Hassan AMA
Comput Biol Chem; 2019 Jun; 80():79-89. PubMed ID: 30928871
[TBL] [Abstract][Full Text] [Related]
20. Licochalcone A, a natural inhibitor of c-Jun N-terminal kinase 1.
Yao K; Chen H; Lee MH; Li H; Ma W; Peng C; Song NR; Lee KW; Bode AM; Dong Z; Dong Z
Cancer Prev Res (Phila); 2014 Jan; 7(1):139-49. PubMed ID: 24253317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
